August 9, 2017 / 10:16 AM / 3 months ago

BRIEF-Array Biopharma reports Q4 loss per share $0.17

Aug 9 (Reuters) - Array Biopharma Inc

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

* Q4 loss per share $0.17

* Q4 revenue $33.8 million versus I/B/E/S view $28.6 million

* Q4 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S

* Array Biopharma Inc - ‍Entered into a license, development and commercialization partnership with Ono Pharmaceutical for binimetinib and encorafenib​

* Array Biopharma Inc - ‍Ono received rights to develop and commercialize binimetinib and encorafenib in Japan and South Korea​

* Array Biopharma - ‍Received upfront payment of $31.2 million, retains exclusive commercialization rights for binimetinib, encorafenib in U.S., Canada, Israel​

* Array Biopharma Inc - ‍Is entitled to receive up to an additional $156 million (¥17.3 billion) if certain development and commercial milestones are achieved​

* Array Biopharma Inc - ‍Will be eligible for robust, tiered, double-digit royalties based on product sales in Japan and South Korea​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below